Inventiva (NASDAQ:IVA) Shares Gap Up Following Analyst Upgrade

Key Points

• Inventiva's share price rose significantly after Guggenheim raised its price target from $9.00 to $13.00, leading to a gap up at market open from $5.26 to $5.74.
• Piper Sandler initiated coverage on Inventiva, giving it an "overweight" rating and a price target of $26.00, contributing to positive sentiment around the stock.
• Currently, institutional investors own 19.06% of Inventiva's stock, indicating growing interest from larger financial entities.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report)'s share price gapped up before the market opened on Wednesday after Guggenheim raised their price target on the stock from $9.00 to $13.00. The stock had previously closed at $5.26, but opened at $5.74. Guggenheim currently has a buy rating on the stock. Inventiva shares last traded at $5.66, with a volume of 22,875 shares traded.

Separately, Piper Sandler started coverage on Inventiva in a report on Wednesday, August 27th. They set an "overweight" rating and a $26.00 price target for the company. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $14.83.

Institutional Investors Weigh In On Inventiva

An institutional investor recently bought a new position in Inventiva stock. Creative Planning acquired a new position in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 10,000 shares of the company's stock, valued at approximately $32,000. 19.06% of the stock is currently owned by institutional investors.

Inventiva Stock Performance

The business has a 50 day moving average of $3.75 and a 200 day moving average of $3.41.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.